Cresset Group news

Antibodies (immunoglobulins) are a key component of the mammalian immune response and are increasingly of interest as a means of therapy for several diseases. In fact, there are over 100 monoclonal antibodies that have been approved as drugs¹. Despite this apparent success, there are issues with biopharmaceutical antibody research and development – not least the cost of goods.  Although it can be argued that therapeutic antibody development relies on semi-random search-a